Press Releases

Data Safety Monitoring Board Gives Positive Review for BioMS Medical's Pivotal MS Trial

- Second Recommendation from Data Safety Monitoring Board -

Edmonton, Alberta, October 27, 2005 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that following the second meeting of its independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. This second recommendation by the DSMB members was based on their recent review of the safety data from patients who have been dosed in the pivotal phase II/III clinical study.

"This recommendation represents solid and steady progress of our lead drug candidate MBP8298,” said Kevin Giese, President of BioMS Medical. “MBP8298 is indeed the most advanced drug candidate in clinical testing for secondary progressive MS. Accordingly, we are pleased with the safety profile obtained in patients up to this point.”

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. The pivotal phase II/III study is now ongoing at trial sites across Canada, the U.K. and Sweden.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.